Vera Therapeutics (VERA) Competitors $30.80 -0.14 (-0.45%) Closing price 04:00 PM EasternExtended Trading$30.80 0.00 (0.00%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VERA vs. GRFS, RYTM, RNA, ABVX, LEGN, CYTK, NUVL, AXSM, TGTX, and CRSPShould you be buying Vera Therapeutics stock or one of its competitors? The main competitors of Vera Therapeutics include Grifols (GRFS), Rhythm Pharmaceuticals (RYTM), Avidity Biosciences (RNA), Abivax (ABVX), Legend Biotech (LEGN), Cytokinetics (CYTK), Nuvalent (NUVL), Axsome Therapeutics (AXSM), TG Therapeutics (TGTX), and CRISPR Therapeutics (CRSP). These companies are all part of the "pharmaceutical products" industry. Vera Therapeutics vs. Its Competitors Grifols Rhythm Pharmaceuticals Avidity Biosciences Abivax Legend Biotech Cytokinetics Nuvalent Axsome Therapeutics TG Therapeutics CRISPR Therapeutics Vera Therapeutics (NASDAQ:VERA) and Grifols (NASDAQ:GRFS) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, risk, valuation, dividends, analyst recommendations, earnings and institutional ownership. Do analysts prefer VERA or GRFS? Vera Therapeutics currently has a consensus target price of $63.00, indicating a potential upside of 104.55%. Grifols has a consensus target price of $10.30, indicating a potential upside of 7.40%. Given Vera Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Vera Therapeutics is more favorable than Grifols.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vera Therapeutics 1 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.60Grifols 0 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50 Which has preferable earnings & valuation, VERA or GRFS? Grifols has higher revenue and earnings than Vera Therapeutics. Vera Therapeutics is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVera TherapeuticsN/AN/A-$152.15M-$3.58-8.60Grifols$7.81B0.84$169.80M$1.178.20 Which has more risk and volatility, VERA or GRFS? Vera Therapeutics has a beta of 1.23, suggesting that its stock price is 23% more volatile than the S&P 500. Comparatively, Grifols has a beta of 0.69, suggesting that its stock price is 31% less volatile than the S&P 500. Does the media refer more to VERA or GRFS? In the previous week, Vera Therapeutics and Vera Therapeutics both had 4 articles in the media. Vera Therapeutics' average media sentiment score of 1.82 beat Grifols' score of 0.83 indicating that Vera Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vera Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Grifols 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders hold more shares of VERA or GRFS? 99.2% of Vera Therapeutics shares are held by institutional investors. 16.3% of Vera Therapeutics shares are held by insiders. Comparatively, 0.2% of Grifols shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Is VERA or GRFS more profitable? Grifols' return on equity of 0.00% beat Vera Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Vera TherapeuticsN/A -46.70% -39.46% Grifols N/A N/A N/A SummaryVera Therapeutics and Grifols tied by winning 7 of the 14 factors compared between the two stocks. Get Vera Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VERA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VERA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VERA vs. The Competition Export to ExcelMetricVera TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.97B$3.32B$6.11B$10.53BDividend YieldN/A2.29%5.51%4.67%P/E Ratio-8.6021.6185.6926.92Price / SalesN/A424.41583.01184.15Price / CashN/A46.3226.3031.10Price / Book3.3910.0613.246.71Net Income-$152.15M-$52.22M$3.30B$276.35M7 Day Performance5.99%5.87%4.64%3.10%1 Month Performance27.33%12.07%8.36%10.19%1 Year Performance-23.02%26.14%87.97%40.37% Vera Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VERAVera Therapeutics2.7838 of 5 stars$30.80-0.5%$63.00+104.5%-24.2%$1.97BN/A-8.6040Positive NewsGRFSGrifols3.7816 of 5 stars$9.93+1.1%$10.30+3.7%+7.7%$6.75B$7.81B8.4923,822Short Interest ↑RYTMRhythm Pharmaceuticals3.5485 of 5 stars$100.64+1.5%$106.64+6.0%+97.2%$6.59B$130.13M-33.44140RNAAvidity Biosciences2.4846 of 5 stars$42.63-0.7%$68.32+60.3%-2.4%$6.27B$10.90M-11.97190ABVXAbivax2.884 of 5 stars$83.33+0.6%$102.14+22.6%+786.2%$6.26BN/A0.0061News CoverageAnalyst ForecastLEGNLegend Biotech2.8288 of 5 stars$32.85-1.6%$74.22+125.9%-35.9%$6.16B$627.24M-37.332,609Analyst ForecastCYTKCytokinetics3.8496 of 5 stars$53.89+6.9%$75.71+40.5%+7.0%$6.03B$18.47M-10.57250Trending NewsAnalyst ForecastInsider TradeNUVLNuvalent3.2472 of 5 stars$84.84+4.2%$119.50+40.9%-20.1%$5.87BN/A-17.3140AXSMAxsome Therapeutics4.7894 of 5 stars$117.62+0.7%$177.86+51.2%+38.5%$5.83B$385.69M-23.20380TGTXTG Therapeutics4.3542 of 5 stars$36.83+3.7%$48.00+30.3%+65.4%$5.63B$329M99.54290Analyst ForecastAnalyst RevisionCRSPCRISPR Therapeutics1.744 of 5 stars$63.77+3.4%$71.50+12.1%+54.7%$5.61B$37.31M-11.74460 Related Companies and Tools Related Companies Grifols Competitors Rhythm Pharmaceuticals Competitors Avidity Biosciences Competitors Abivax Competitors Legend Biotech Competitors Cytokinetics Competitors Nuvalent Competitors Axsome Therapeutics Competitors TG Therapeutics Competitors CRISPR Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VERA) was last updated on 10/7/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vera Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
